Genuity Capital Markets
http://www.genuitycm.com/Genuity Capital Markets is a financial services firm providing investment banking, institutional sales and trading, and equity research to its corporate clients. The firm uses a simple Buy, Hold and Sell rating system in its research analysis.
View Older Stories View More Recent Stories
-
Canaccord Genuity on Life Sciences/Biotechnology: FDA �Flexibility� May Add To Advantages of Orphan Drugs in Today's Market
-
Canaccord Genuity reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Encouraging Data Points Picked Up During Management/Investor Meeting
-
Canaccord Genuity Maintains a 'Hold' on Westport Innovations (WPRT); Powering Up the Portfolio Part II: Analyst Day Notes
-
Canaccord Genuity Maintains a 'Buy' on ICF International (ICFI); Q3 Earnings Preview
-
Canaccord Genuity Maintains a 'Sell' on Aixtron (AIXG); Cutting Estimates & Price Target
-
UPDATE - Canaccord Genuity Downgraded Veeco Instruments (VECO) to 'Sell' on Cut in Forecasts
-
Canaccord Genuity Upgrades Minefinders Corp. (MFN) to Buy
-
Canaccord Genuity Downgrades Veeco Instruments Inc. (VECO) to Sell
-
Canaccord Genuity Reiterates a 'Buy' on Tranzyme (TZYM); Ulimorelin Phase 3 Enrollment Progressing Well
-
Canaccord Genuity Maintains a 'Hold' on Micromet (MITI); B-mab Development Plan Solidifies
-
Canaccord Genuity Reiterates a 'Buy' on Medicis (MRX); Takeout Speculation Likely to Continue
-
Canaccord Genuity on Consumer & Retail/Footwear and Apparel: Does the NBA Lockout Really Matter?
-
Canaccord Genuity Reiterates a 'Buy' on Solta Medical (SLTM); Notes From the Road
-
Canaccord Genuity Reiterates a 'Buy' on Meridian Biosciences (VIVO); Thesis Review Following Road Trip
-
Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Management Meeting Takeaways: Nuedexta European MAA on Track for Year-End Filing
-
Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Settlement with Bayer Removes Big Overhang
-
Canaccord Genuity Maintains an 'Buy' on Schnitzer Steel (SCHN); August Quarter Earnings Preview
-
Microsemi (MSCC) Completes Zalink Acquisition, Extends Tender Offer
-
Canaccord Genuity Life Sciences/Specialty Pharmaceuticals: Three Catalysts With Potential To Drive Upside by Year-End - TEVA, WCRX & WPI
-
Canaccord Genuity Reiterates a 'Buy' on InterMune (ITMN); Hallo Esbriet: New German Pricing Process May Let Other Countries Delay Pricing
-
Canaccord Genuity Maintains a 'Buy' on Inhibitex (INHX); Big Catalysts Expected Over Next 12 Months
-
Canaccord Genuity Maintains a 'Buy' on Jones Lang LaSalle (JLL); Reducing Estimates on Slower Real Estate Market Growth
-
Canaccord Genuity Downgrades Lloyds TSB Group (LYG) to Hold
-
Canaccord Genuity on Life Sciences -- Biomedical Devices and Services: CQ3/11 Med-Tech Preview
-
Notable Analyst Rating Changes 10/11: (NUE) (SFD) (ARO) Upgraded; (COP) (PDLI) (STP) Downgraded
-
Canaccord Genuity Starts Mylan (MYL) at Hold
-
Canaccord Genuity Starts Perrigo Co. (PRGO) at Hold
-
Canaccord Genuity Starts Impax Laboratories (IPXL) at Hold
-
Canaccord Genuity Maintains a 'Buy' on IMRIS (IMRS); Lowering Estimates and Price Target
-
Canaccord Genuity Maintains a 'Hold' on RPC Inc. (RES); Still Pricing in Some Acquisition Potential
-
Canaccord Genuity maintains a 'Buy' on EOG Resources (EOG); Liquids Growth on Track; Potential Value Uplift from Improving Price Realizations
-
Research in Motion (RIMM) volatility stays elevated at 79
-
Canaccord Genuity on Life Sciences/Biotechnology: Maintains 'Buy' on MNTA & WPI
-
Canaccord Genuity Reiterates a 'Hold' on Research In Motion (RIMM); Checks Indicate Solid Initial BB 7 Sales; L-T Concerns Make Premium Take-Out Valuation Unlikely
-
Canaccord Genuity Reiterates a 'Buy' on Apple (AAPL); Checks Indicate Strong Initial iPhone 4S Pre-orders, Legacy Model Sales
-
Canaccord Genuity Maintains a 'Buy' on Pioneer Natural Resources (PXD); Production Momentum Bodes Well for Q3/11; Strong Hedge Position
-
Canaccord Genuity maintains a 'Buy' on Cytokinetics (CYTK); A closer look - CK357 Dizziness: May Not Be Dealbreaker in ALS
-
Canaccord Genuity Reiterates a 'Buy' on AngioDynamics (ANGO); Good Start for New CEO
-
Canaccord Genuity Downgrades GLG Life Tech Corporation (GLGL) to Hold; No Longer Stomaching the Aftertaste of Consistent Disappointment
-
Canaccord Genuity Reiterates a 'Buy' on Oracle (ORCL); Best Positioned Platform Vendor
-
Canaccord Genuity Reiterates a 'Buy' on Anaren (ANEN); Soft Wireless Sales and Push-out of Space & Defense Contracts Force Pre-Announcement
-
Canaccord Genuity Reiterates a 'Buy' on Teva Pharma (TEVA); Catalysts Ahead
-
Canaccord Genuity Reiterates a 'Buy' on Raptor Pharmaceuticals (RPTP); Cystinosis Doctor Call Takeaways: ~5x Better Compliance, Patient Outcomes Possible with RP103
-
Canaccord Genuity Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); C-Mib Reg Catalysts Ahead
-
Canaccord Genuity Reiterates a 'Buy' on Integra LifeSciences (IART); Ascension Acquisition Complete; Unique Technology & Broadens Market
-
Canaccord Genuity Maintains a 'Hold' on LKQ Corp (LKQX); Raising 2012 Estimates on ECP Acquisition
-
Canaccord Genuity Reiterates a 'Buy' on Apple (AAPL); Thesis Fully Intact Despite Death of Legend
-
Canaccord Genuity Maintains a 'Hold' on Baker Hughes (BHI); Attractive After Declines, but Peers Cheaper
-
Canaccord Genuity Reiterates a 'Buy' on Quidel Corp. (QDEL) After Meeting With Management
-
Canaccord Genuity Maintains a 'Buy' on Kadant; Lowering Numbers on More Conservative Outlook
